Novo Up 4% in a Month: How Should Investors Approach the Stock Now?

Impact · against what's priced in

The news is largely neutral for LLY and NVO as the market had already integrated the GLP-1 competitive dynamics and guidance updates. While Novo's guidance raise and oral sales are positive, they function as confirmation of the current trajectory rather than new catalysts.

LLY−0.10

Already priced in

The price assumes

Oral Foundayo Market Penetration vs. Novo Nordisk Oral Wegovy

The reported DKK 5.39 billion in third-quarter sales for Novo's oral obesity drug and 8 million U.S. prescriptions confirm the competitive pressure the market expects from Novo's oral franchise.

What LLY's price assumes · Sep 10

• guidance▲16%
• earnings▲4%
• healthcare▲3%
• pharmaceuticals
• LLY
• NVO
• glp 1